Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of Arfolitixorin Combined With 5-fluorouracil, Oxaliplatin, and Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

Next Previous
Trial Profile

A Phase 1b/2 Study of Arfolitixorin Combined With 5-fluorouracil, Oxaliplatin, and Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arfolitixorin (Primary) ; Bevacizumab; Fluorouracil; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Isofol Medical

Most Recent Events

  • 24 Feb 2026 According to Isofol Medical media release, the study will be expanded beyond Charite to several other hospitals in order to enable swift patient enrollment. Results from the ongoing study will be presented at upcoming medical congresses during the year.
  • 24 Feb 2026 Results presented in the Isofol Medical Media Release.
  • 20 Jan 2026 According to Isofol Medical media release, An abstract describing the study design for ongoing phase Ib/II clinical study with arfolitixorin has been accepted for presentation at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancer) Symposium in San Francisco, US, January 8-10.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top